Memory fixation accelerator
    2.
    发明授权
    Memory fixation accelerator 有权
    记忆固定加速器

    公开(公告)号:US08431613B2

    公开(公告)日:2013-04-30

    申请号:US13459959

    申请日:2012-04-30

    CPC分类号: A61K31/192 A61K31/695

    摘要: A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.

    摘要翻译: 一种用于促进记忆巩固的药物,其包含作为活性成分的非天然类视黄醇,优选具有基本骨架的类视黄醇,所述基本骨架包含通过桥连基团与芳族羧酸或托洛替林结合的芳环,更优选4 - [(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸或4 - [(3,5-双三甲基甲硅烷基苯基) - 甲酰胺基]苯甲酸。

    MEMORY FIXATION ACCELERATOR
    3.
    发明申请
    MEMORY FIXATION ACCELERATOR 有权
    存储器固定加速器

    公开(公告)号:US20120214763A1

    公开(公告)日:2012-08-23

    申请号:US13459959

    申请日:2012-04-30

    IPC分类号: A61K31/695 A61P25/28

    CPC分类号: A61K31/192 A61K31/695

    摘要: A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.

    摘要翻译: 一种用于促进记忆巩固的药物,其包含作为活性成分的非天然类视黄醇,优选具有基本骨架的类视黄醇,所述基本骨架包含通过桥连基团与芳族羧酸或托洛替林结合的芳环,更优选4 - [(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸或4 - [(3,5-双三甲基甲硅烷基苯基) - 甲酰胺基]苯甲酸。

    Compound having heterocyclic ring
    4.
    发明授权
    Compound having heterocyclic ring 失效
    具有杂环的化合物

    公开(公告)号:US08148362B2

    公开(公告)日:2012-04-03

    申请号:US12225819

    申请日:2007-03-30

    IPC分类号: A61K31/00 C07D255/00

    摘要: The invention provides a novel oxazolidinone derivative represented by the formula (I): wherein Ring A is optionally substituted or fused and represents (A-1) at least 7-membered monocyclic hetero ring containing at least three N atoms; (A-2) at least 6-membered monocyclic hetero ring containing at least two N atoms and at least one O atom; or (A-3) at least 7-membered monocyclic hetero ring containing at least two N atoms and at least one S atom; X1 is a single bond, —O—, —S—, —NR2—, —CO—, —CS—, —CONR3—, —NR4CO—, —SO2NR5—, and —NR6SO2— (wherein R2-R6 are independently hydrogen or lower alkyl), or lower alkylene or lower alkenylene in which one of the preceding groups may intervene; Ring B is optionally substituted carbocycle or optionally substituted heterocycle; R1 is hydrogen, or an organic residue which is able to bind to the 5-position of oxazolidinone ring in oxazolidinone antimicrobial agent, and an antibacterial agent containing the same.

    摘要翻译: 本发明提供由式(I)表示的新型恶唑烷酮衍生物:其中环A任选被取代或稠合并且代表(A-1)含有至少三个N原子的至少七元单环杂环; (A-2)至少含有至少两个N原子和至少一个O原子的6元单环杂环; 或(A-3)至少含有至少两个N原子和至少一个S原子的7元单环杂环; X 1是单键,-O - , - S - , - NR 2 - , - CO - , - C - , - CONR 3 - , - NR 4 CO-,-SO 2 NR 5 - 和-NR 6 SO 2 - 或低级烷基)或其中一个前述基团可以介入的低级亚烷基或低级亚烯基; 环B是任选取代的碳环或任选取代的杂环; R1是氢,或能够与恶唑烷酮抗微生物剂中的恶唑烷酮环的5位结合的有机残基,以及含有该残基的抗菌剂。

    Tricyclic amine compound
    5.
    发明授权
    Tricyclic amine compound 失效
    三环胺化合物

    公开(公告)号:US08143260B2

    公开(公告)日:2012-03-27

    申请号:US12673221

    申请日:2008-08-14

    摘要: A compound represented by the following general formula (I): [wherein R1 represents hydrogen atom or a C1-6 alkyl group, A and B represent —(CH2)2—, —(CH2)3— or —(CH2)4—, X represents —N(R2)— (R2 represents hydrogen atom or a C1-6 alkyl group), —CO—, —C(═N—R3)— (R3 represents hydrogen atom or a C1-6 alkyl group), or —C(═C(R4)(R5))— (R4 and R5 independently represent hydrogen atom or a C1-6 alkyl group), and Ar represents an aryldiyl group or a heteroaryldiyl group], which has an action of controlling physiological activities of retinoids and useful as an active ingredient of a medicament.

    摘要翻译: 由下列通式(I)表示的化合物:[其中R1表示氢原子或C1-6烷基,A和B表示 - (CH2)2-, - (CH2)3-或 - (CH2)4- ,X表示-N(R 2) - (R 2表示氢原子或C 1-6烷基),-CO-,-C(= N-R 3) - (R 3表示氢原子或C 1-6烷基) 或-C(= C(R4)(R5)) - (R4和R5独立地表示氢原子或C1-6烷基),Ar表示芳基二基或杂芳基二基],其具有控制生理 类维生素A的活性并且可用作药物的活性成分。

    Anti-wrinkle agent
    6.
    发明授权
    Anti-wrinkle agent 有权
    抗皱剂

    公开(公告)号:US08030360B2

    公开(公告)日:2011-10-04

    申请号:US12040374

    申请日:2008-02-29

    IPC分类号: A61K31/07 A61K8/00

    摘要: A medicament having an anti-wrinkle action, which comprises as an active ingredient a retinoid having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid (for example, 4-(3,5-bis(trimethylsilyl)phenylcarboxamide) benzoic acid, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid, or the like).

    摘要翻译: 具有抗皱作用的药物,其包含具有苯基取代的氨基甲酰基苯甲酸或苯基取代的酰胺苯甲酸的基本结构的类视黄醇作为活性成分(例如,4-(3,5-双(三甲基甲硅烷基) 苯基甲酰胺)苯甲酸,4 - [(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸等)。

    OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING
    7.
    发明申请
    OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING 失效
    具有7层杂环的氧杂环丁酮衍生物

    公开(公告)号:US20100256355A1

    公开(公告)日:2010-10-07

    申请号:US12733954

    申请日:2008-10-01

    摘要: The present invention provides a novel oxazolidinone derivative of the formula (I): wherein Ring A is (A-1) a 7-membered monocyclic heterocycle containing three N atoms; (A-2) a 7-membered monocyclic heterocycle containing two N atoms and one O atom; or (A-3) a 7-membered monocyclic heterocycle containing two N atoms and one S atom, SO or SO2, wherein said monocyclic heterocycle is optionally substituted, optionally unsaturated and optionally fused with another ring; X1 is a single bond, or a heteroatom-containing group selected from the group consisting of —O—, —S—, —NR2—, —CO—, —CS—, —CONR3—, —NR4CO—, —SO2NR5—, and —NR6SO2—, wherein R2, R3, R4, R5 and R6 are independently hydrogen or lower alkyl, or lower alkylene or lower alkenylene each optionally interrupted by said heteroatom-containing group; Ring B is optionally substituted carbocycle or optionally substituted heterocycle; and R1 is hydrogen, or an organic residue which is able to bind to the 5-position of the oxazolidinone ring in oxazolidinone antimicrobial agents, pharmaceutically acceptable salts and solvates thereof which are useful as an antibacterial agent.

    摘要翻译: 本发明提供式(I)的新型恶唑烷酮衍生物:其中环A为(A-1)含有三个N原子的7-元单环杂环; (A-2)含有两个N原子和一个O原子的7-元单环杂环; 或(A-3)含有两个N原子和一个S原子,SO或SO 2的7-元单环杂环,其中所述单环杂环任选被取代,任选地不饱和且任选地与另一个环稠合; X 1为单键或选自-O - , - S - , - NR 2 - , - CO - , - CS - , - CONR 3 - , - NR 4 CO - , - SO 2 NR 5 - 和-NR 6 SO 2 - ,其中R 2,R 3,R 4,R 5和R 6独立地为氢或低级烷基,或低级亚烷基或低级亚烯基,各自任选被所述含杂原子基团中断; 环B是任选取代的碳环或任选取代的杂环; R 1为氢,或可用于作为抗菌剂使用的恶唑烷酮抗微生物剂,其药学上可接受的盐和溶剂合物中的恶唑烷酮环的5位的有机残基。

    METHOD FOR TREATING VASCULAR DISEASE
    8.
    发明申请
    METHOD FOR TREATING VASCULAR DISEASE 审中-公开
    治疗血管疾病的方法

    公开(公告)号:US20090253796A1

    公开(公告)日:2009-10-08

    申请号:US12412678

    申请日:2009-03-27

    IPC分类号: A61K31/196 A61P9/10

    摘要: A medicament for prophylactic and/or therapeutic treatment of a vascular disease such as vascular restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent, which comprises as an active ingredient a substance selected from the group consisting of retinoids and agents for controlling actions of retinoids such as 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or a salt thereof, or 4-[[[3,5-bis-(trimethylsilyl)phenyl]carbonyl]amino]benzoic acid or a salt thereof, wherein said substance has substantially no antiproliferative action on vascular endothelial cells, but substantially has antiproliferative action on vascular smooth muscle cells.

    摘要翻译: 用于使用血管内支架的经皮腔内冠状动脉成形术之后的血管疾病如血管再狭窄和/或再闭塞的预防和/或治疗性治疗药物,其包含选自维甲酸类和控制剂的活性成分 类维生素如4- [5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸或其盐或4 - [[[3,5- - 双(三甲基甲硅烷基)苯基]羰基]氨基]苯甲酸或其盐,其中所述物质对血管内皮细胞基本上没有抗增殖作用,但对血管平滑肌细胞基本具有抗增殖作用。

    Medicament for preventive and/or therapeutic treatment of diseases with secretory disorder
    9.
    发明申请
    Medicament for preventive and/or therapeutic treatment of diseases with secretory disorder 审中-公开
    用于预防和/或治疗分泌性疾病疾病的药物

    公开(公告)号:US20080139842A1

    公开(公告)日:2008-06-12

    申请号:US11854697

    申请日:2007-09-13

    IPC分类号: C07C229/00

    CPC分类号: A61K31/192

    摘要: A medicament for preventive and/or therapeutic treatment of a secretory dysfunctional disease associated with lymphocyte infiltration into a gland such as type I diabetes or Sjogren's syndrome, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.

    摘要翻译: 用于预防和/或治疗与淋巴细胞浸润相关的分泌功能障碍性疾病的药物,所述分泌功能障碍性疾病包括作为活性成分的类视黄醇例如4 - [(5, 6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸。

    Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation
    10.
    发明申请
    Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation 审中-公开
    血管再通术后再狭窄或再闭塞的治疗和/或预防性治疗药物

    公开(公告)号:US20070254956A1

    公开(公告)日:2007-11-01

    申请号:US10577487

    申请日:2004-10-28

    CPC分类号: A61K31/167

    摘要: A medicament for therapeutic and/or preventive treatment of restenosis or reocclusion after a vascular recanalization operation, which comprises as an active ingredient a compound represented by the following formula or a physiologically acceptable salt thereof, and a medical device for an intravascular treatment, which contains said compound or the physiologically acceptable salt thereof in a releasable form.

    摘要翻译: 一种用于治疗和/或预防治疗血管再通气手术后的再狭窄或再闭塞的药物,其包含作为活性成分的由下式表示的化合物或其生理学上可接受的盐以及用于血管内治疗的医疗装置,其包含 所述化合物或其生理上可接受的盐以可释放的形式存在。